Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

6.700
-0.140-2.05%
Volume:2.27M
Turnover:15.17M
Market Cap:7.05B
PE:-18.10
High:6.890
Open:6.840
Low:6.500
Close:6.840
52wk High:19.860
52wk Low:6.500
Shares:1.05B
HK Float Shares:1.05B
Volume Ratio:0.79
T/O Rate:0.22%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.370
ROE:-28.59%
ROA:-19.64%
PB:2.65
PE(LYR):-18.10
PS:6347.32

Loading ...

Ascletis-B Repurchases 200,000 Shares on 13 Oct; Outstanding Buybacks Awaiting Cancellation Rise to 2.05 Million

Bulletin Express
·
Yesterday

Ascletis Pharma Reports Additional Share Buyback; 200,000 Shares Repurchased on 12 Oct 2026

Bulletin Express
·
Oct 12

Ascletis Pharma-B Repurchases 200,000 Shares for Approximately HK$1.3703 Million on October 12

Stock News
·
Oct 12

Hong Kong Stock Market Movers: Innovative Drug Stocks Deepen Losses in Afternoon Session, Ascletis Pharma-B (01672) Falls Over 10%, Innovent Bio (01801) Drops Nearly 4%

Stock News
·
Oct 08

ASCLETIS-B Issues 0.22 Million New Shares on Option Exercises in September, Maintains Compliant Public Float

Bulletin Express
·
Oct 06

Ascletis Pharma Climbs Nearly 11% in Afternoon Trading as Preclinical Data for Weight-Loss Combination Therapy ASC36_35FDC Is Released

Deep News
·
Oct 06

Hong Kong Stock Movers: Innovative Drug Stocks Extend Gains as BofA Points to Three Major Recent Partnerships Strengthening Sector Momentum and ESMO Set to Bring Dense Catalysts

Stock News
·
Oct 06

HK Movers | Innovative Drug Stocks Rally Broadly; GENSCRIPT BIO Jumps Over 6% to New High

Tiger Newspress
·
Oct 06

NIO-SW Delivers 300,301 Vehicles in First Three Quarters, Up 49.2% Year-on-Year

Stock News
·
Oct 05

Ascletis Pharma Presents Preclinical Data for Weight Loss Drug at European Conference

MT Newswires Live
·
Oct 02

Ascletis’ ASC36_35FDC Shows Up to 24.8% Weight-Loss and Once-Quarterly Potential in Preclinical Studies

Bulletin Express
·
Oct 02

Ascletis Pharma-B Reports Promising Preclinical Data for ASC36_35FDC at EASD 2026, Showing Potential for Monthly to Quarterly Dosing and Robust Weight Loss

Stock News
·
Oct 02

Ascletis Pharma Widens H1 2026 Loss to RMB 0.32 Billion as R&D Outlays Double; Cash Pile Rises to RMB 2.31 Billion

Bulletin Express
·
Sep 29

Ascletis Pharma Reports Positive Results From ASC50 Psoriasis Trial

MT Newswires Live
·
Sep 29

Ascletis Reports 48.9% Placebo-Adjusted PASI Reduction in U.S. Proof-of-Concept Study for First-in-Class Oral IL-17A Inhibitor ASC50

Bulletin Express
·
Sep 29

Ascletis Says ASC50 Cuts PASI Score 48.9% in 28-Day U.S. Plaque Psoriasis Study

Reuters
·
Sep 29

Ascletis Pharma-B (01672) Reports Positive 28-Day Proof-of-Concept Clinical Results for First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor ASC50 in Treating Plaque Psoriasis in the United States

Stock News
·
Sep 29

Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for Asc50, a First-in-Class and Best-in-Class Oral Small Molecule Il-17a Inhibitor for the Treatment of Plaque Psoriasis

THOMSON REUTERS
·
Sep 29

HK Stocks in Focus: Biopharma Sector Surges as 10 Ministries Unveil 15th Five-Year Plan; Analysts See Potential 'Claude Moment' for Industry

Stock News
·
Sep 18

Ascletis Pharma Surges on US Obesity Drug Trial Launch

Deep News
·
Sep 10